803 results on '"Maher, T."'
Search Results
2. Predicting the Maximum Axial Capacity of Secant Pile Walls Embedded in Sandy Soil
3. Theoretical models validation of Cr -51 production reactions for medical applications
4. A review on recent advances on improving fuel economy and performance of a fuel cell hybrid electric vehicle
5. Emergent chiral spin textures in centrosymmetric iron garnet with spin alignment constraints
6. Performance Analysis of Axially Loaded Secant Pile Wall Embedded in Sand: An Experimental Investigation
7. A metal-free electrochemically exfoliated graphene/graphitic carbon nitride nanocomposite for CO2 photoreduction to methane under visible light irradiation
8. Electrochemical exfoliation of graphene using dual graphite electrodes by switching voltage and green molten salt electrolyte
9. Effect of graphite exfoliation routes on the properties of exfoliated graphene and its photocatalytic applications
10. Classification of Patients With Idiopathic Pulmonary Fibrosis According to Blood Biomarker Signatures by Consensus Cluster Analysis: A Multiple Machine Learning Approach
11. A Comparison of the Pupillary and Electrodermal Components of the Orienting Reflex in Sensitivity to Initial Stimulus Presentation, Repetition, and Change
12. The Australian Square Kilometre Array Pathfinder: System Architecture and Specifications of the Boolardy Engineering Test Array
13. Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis
14. Inhibition of Fatty Acid Amide Hydrolase (FAAH) by Macamides
15. Coconut oil has less satiating properties than medium chain triglyceride oil
16. POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
17. POS0845 EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN PATIENTS WITH PROGRESSIVE FIBROSING AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES
18. Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4B, in Patients with Idiopathic Pulmonary Fibrosis: a Phase 2 Trial*
19. Design of Phase III, Randomized, Placebo-Controlled Trials of BI 1015550 in Patients with Progressive Fibrosing Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis (FIBRONEER-ILD / -IPF)
20. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial*
21. An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
22. Effect of nintedanib on circulating biomarkers in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)*
23. Interim results from AIR, an open-label, single arm, 36-week ph 2 trial of C21 in subjects with idiopathic pulmonary fibrosis
24. Dorsal metacarpal veins: anatomic variation and potential clinical implications
25. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
26. S2 Nocturnal hypoxaemia rather than obstructive sleep apnoea is associated with progressive deterioration in quality of life in patients with fibrotic interstitial lung disease
27. Supplementary data: The burden and impact of cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study.
28. Morphometric Analysis of the Foramen Magnum/ Análisis Morfometrico del Foramen Magno
29. Impact of weight loss on outcomes in patients with progressive fibrosing interstitial lung diseases (ILDs)
30. A transcriptomic, metabolic and phenotypic study of the anti-fibrotic effects of PGE2 in IPF lung fibroblasts and macrophages
31. A modified blood cell GAP (cGAP) to prognosticate outcomes in IPF
32. A phase 2b randomized trial to evaluate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF)
33. Progression of systemic sclerosis-associated ILD (SSc-ILD) and effect of nintedanib in subgroups by monocyte and neutrophil counts
34. Association of mUC5B rs35705950 minor allele with age and survival in European patients with Idiopathic Pulmonary Fibrosis
35. Additive effect of BI 1015550 and nintedanib in patients with IPF
36. Validity and symptom burden of impulse oscillometry (iOS) in idiopathic pulmonary fibrosis (IPF)
37. Nocturnal hypoxaemia is associated with mortality in patients with fibrotic interstitial lung disease
38. GALACTIC-1: Galectin-3 inhibition in idiopathic pulmonary fibrosis (IPF) – rationale, objectives and design of a 52-week, Phase IIb study of GB0139
39. Limited utility of STOP-BANG in identification of obstructive sleep apnoea in fibrotic interstitial lung disease
40. An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
41. Endothelial progenitor cell-derived small extracellular vesicles for myocardial angiogenesis and revascularization
42. Deferring treatment with pirfenidone results in loss of lung function that is not recovered by later treatment initiation: M28
43. Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials: M30
44. Differences in patient and physician viewpoints of the management of idiopathic pulmonary fibrosis (ipf): M19
45. The impact of azithromycin in idiopathic pulmonary fibrosis: S56
46. Predictors of uptake of ambulatory oxygen on completion of the ambox trial, a study to assess effects of ambulatory oxygen on quality of life in patients with fibrotic interstitial lung disease: S57
47. The effects of a novel formulation of inhaled cromolyn sodium (pa101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, controlled, phase 2 trial: S34
48. POS0385 “EFFECTIVE LUNG AGE” IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) IN THE SENSCIS TRIAL
49. OP0157 EFFECT OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) AND RISK FACTORS FOR RAPID DECLINE IN FORCED VITAL CAPACITY: FURTHER ANALYSES OF THE SENSCIS TRIAL
50. POS0853 EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.